{"entity":{"id":"nct04524689","kind":"trial","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","aka":[],"tldr":"A phase 2 trial of Tusamitamab ravtansine, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in Non-small-cell lung cancer, run by Sanofi, recorded as terminated on the registry.","summary":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC is a phase 2 interventional study registered as NCT04524689 by Sanofi, with 57 participants recorded, started 2020-10-26 and due to reach its primary completion in 2024-03-12. Interventions recorded: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed. Conditions recorded: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC).\n\nLinked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04524689","url":"https://clinicaltrials.gov/study/NCT04524689"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["tusamitamab-ravtansine","pembrolizumab","cisplatin","carboplatin","pemetrexed"],"companies":["sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04524689","phase":"2","setting":"Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)","sponsor":"Sanofi","started":"2020-10-26","startedType":"actual","yearReported":2025,"enrolled":57,"enrolledBasis":"registry","outcomes":[{"endpoint":"Doublet Cohort: Objective Response Rate (ORR)","primary":true,"unit":"%","arms":[{"name":"Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab","n":23,"value":47.8,"note":"95% CI 26.82 to 69.41; Figures from the ClinicalTrials.gov results section (first posted 2025-03-17), not from a publication"},{"name":"Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab","n":2,"value":0,"note":"95% CI 0.00 to 84.19"}],"source":"https://clinicaltrials.gov/study/NCT04524689?tab=results"},{"endpoint":"Quadruplet Cohort: Objective Response Rate","primary":true,"unit":"%","arms":[{"name":"Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed","n":22,"value":59.1,"note":"95% CI 36.35 to 79.29; Figures from the ClinicalTrials.gov results section (first posted 2025-03-17), not from a publication"},{"name":"Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab + Cisplatin/Carboplatin + Pemetrexed","n":3,"value":66.7,"note":"95% CI 9.43 to 99.16"}],"source":"https://clinicaltrials.gov/study/NCT04524689?tab=results"}]},"route":"/trials/nct04524689/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/"}],"company":[{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}]}}